Organogenesis Holdings (ORGO) Stock Research

Friday

Organogenesis price target lowered by $1 at Truist

ORGO

Aug 7, 10:18 AM

Over a week ago

Organogenesis Affinity meets primary endpoint in complex venous leg ulcer trial

ORGO

Jul 27, 4:51 PM

Organogenesis announces FDA acceptance of ReNu biologics license application

ORGO

Jul 6, 4:08 PM

Organogenesis initiated with neutral view at Truist, here's why

ORGO

May 28, 6:13 AM

Organogenesis just downgraded at BTIG, here's why

ORGO

May 8, 7:06 AM

Organogenesis completes rolling submission of ReNu BLA

ORGO

Apr 28, 4:51 PM

Midday Fly By: Health insurers get 'positive surprise' from CMS

+30

Apr 7, 12:02 PM

Morning Movers: Broadcom gains following pact to supply custom TPUs for Google

Apr 7, 9:09 AM

Video: Health insurers rise after CMS finalizes 2027 Medicare payment hike

Apr 7, 9:01 AM

Closing Bell Movers: Health insurers rise on higher Medicare rate hike

+14

Apr 6, 8:27 PM

Organogenesis achieves primary endpoint in PuraPly study

ORGO

Apr 6, 7:04 PM

Organogenesis announces successful FDA meeting, plans to file BLA for ReNu

ORGO

Apr 6, 5:31 PM

Organogenesis management to meet with BTIG

ORGO

Mar 13, 3:29 PM

Organogenesis price target lowered by $1 at BTIG, here's why

ORGO

Feb 27, 7:30 AM

What You Missed On Wall Street On Friday

+15

Dec 26, 4:04 PM

Wound-care stocks slip after CMS reverses coverage decision

Dec 26, 12:00 PM

BTIG more cautious on Organogenesis after CMS ruling on skin grafts

ORGO

Dec 26, 8:16 AM

Closing Bell Movers: UiPath up nearly 4% after S&P 400 admission

Dec 23, 6:29 PM

Organogenesis initiates rolling submission of BLA to FDA for ReNu

ORGO

Dec 23, 4:08 PM

Morning Movers: Vital Farms dips after cutting FY25 revenue view

Dec 16, 8:59 AM

Organogenesis plans to file BLA for ReNu before end of December

ORGO

Dec 15, 4:26 PM

Organogenesis price target raised by $2 at BTIG, here's why

ORGO

Nov 20, 7:10 AM

Organogenesis provides update on second Phase 3 ReNu study

ORGO

Sep 25, 4:53 PM

No more stories

Established Product Portfolio & IP: Proprietary, clinically proven products like Apligraf, Dermagraft, and PuraPly provide a strong market presence and high barriers to entry for competitors, backed by extensive intellectual property.

Robust Clinical Efficacy & Data: Extensive and compelling clinical data support the effectiveness and safety of their key products, driving physician adoption and preference in the advanced wound care market.

Favorable Reimbursement Pathways: Well-established and favorable reimbursement coverage for their leading products, such as Apligraf and Dermagraft, ensures broad patient access and consistent revenue streams, a critical factor in medical device adoption.

Regulatory Approval & Compliance Challenges: Delays or failures in obtaining or maintaining FDA and international regulatory approvals for existing products or pipeline candidates could significantly hinder market access and revenue growth.

Reimbursement Uncertainty & Pressure: Adverse changes in healthcare reimbursement policies, coverage decisions by payers, or increasing pricing pressure could negatively impact product adoption and profitability.

Intense Market Competition: Organogenesis operates in highly competitive wound care and regenerative medicine markets, facing established players and new entrants, which could lead to loss of market share or pricing erosion.